Genistein: a promising modulator of apoptosis and survival signaling in cancer.

Hemant Joshi, Isha Rani, Hadi Sajid Abdulabbas, Dhruv Sanjay Gupta, Nosheen Kamruddin Abjani, Ginpreet Kaur, Chakrabhavi Dhananjaya Mohan, Jagjit Kaur, Diwakar Aggarwal, Seema Ramniwas, Madhu Gupta, Hardeep Singh Tuli

Journal: Naunyn-Schmiedeberg's archives of pharmacology 2023;396(11):2893-2910

PMID: 37300702

Full Text on Springer View on PubMed

Abstract

Genistein, a commonly occurring isoflavone, has recently gained popularity owing to its ever-expanding spectrum of pharmacological benefits. In addition to health benefits such as improved bone health and reduced postmenopausal complications owing to its phytoestrogen properties, it has been widely evaluated for its anti-cancer potential. Several studies have established the potential for its usage in the management of breast, lung, and prostate cancers, and its usage has significantly evolved from early applications in traditional systems of medicine. This review offers an insight into its current status of usage, the chemistry, and pharmacokinetics of the molecule, an exploration of its apoptotic mechanisms in cancer management, and opportunities for synergism to improve therapeutic outcomes. In addition to this, the authors have presented an overview of recent clinical trials, to offer an understanding of contemporary studies and explore prospects for a greater number of focused trials, moving forward. Advancements in the application of nanotechnology as a strategy to improve safety and efficacy have also been highlighted, with a brief discussion of results from safety and toxicology studies.

Address: School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India.; Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.; Department of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysore-570006, India.; Graduate School of Biomedical Engineering, Faculty of Engineering, The University of New South Wales, Sydney, 2052, Australia.; Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, 133207, India.; Department of Biochemistry, Maharishi Markandeshwar College of Medical Sciences and Research (MMCMSR), Sadopur, 134007, Ambala, India.; University Centre for Research and Development, University Institute of Pharmaceutical Sciences, Chandigarh University, Gharuan, Mohali, 140413, India.; Continuous Education Department, Faculty of Dentistry, University of Al-Ameed, Karbala, 56001, Iraq.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India.; Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, 133207, India. [email protected].

DOI: 10.1007/s00210-023-02550-1

Link outs

Free resources

Medical:

https://medlineplus.gov/prostatecancer.html

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s00210-023-02550-1

MeSH Terms: Male, Humans, Genistein, Isoflavones, Phytoestrogens, Prostatic Neoplasms, Apoptosis